Thus, IKK inhibition not only disrupts oncogenic NF-κB signaling but also undermines BCL–2–dependent survival mechanisms, providing a promising targeted therapeutic strategy for overcoming the intrinsic resistance of ATLL to conventional treatments. The gene discussed is NFKB1; the disease is adult T-cell leukemia/lymphoma.